Literature DB >> 15384703

[Posterior encephalopathy syndrome in two patients after cancer surgery with transfusion].

Hiroyuki Kawano1, Tomohiro Suga, Tadashi Terasaki, Yoichiro Hashimoto, Kenichiro Baba, Makoto Uchino.   

Abstract

We here report two patients (58-year-old, 77-year-old women) who presented themselves with generalized convulsion, impaired consciousness and hypertension several days after cancer surgery and transfusion. MRI T2 weighted images show an extensive area of increased signal intensity along the occipital cortex, but the underlying white matter revealed slight high signal intensity on diffusion weighted images. Despite similarities of those two cases to posterior leukoencephalopathy syndrome, they differ since the neuroimaging abnormalities are mostly in the occipital cortex. It is likely that the posterior cerebral cortex and white matter are vulnerable to circulatory, vascular and metabolic/toxic impairments. Depending on the abnormalities of many physiological variables, either the subcortical white matter, cortical gray or both might become a major target of this syndrome.

Entities:  

Mesh:

Year:  2004        PMID: 15384703

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  3 in total

1.  Posterior reversible encephalopathy syndrome(PRES).

Authors:  Sreenivasa Rao Sudulagunta; Mahesh Babu Sodalagunta; Monica Kumbhat; Aravinda Settikere Nataraju
Journal:  Oxf Med Case Reports       Date:  2017-04-03

Review 2.  Posterior reversible encephalopathy syndrome with extensive cytotoxic edema after blood transfusion: a case report and literature review.

Authors:  Yoshitsugu Nakamura; Masakazu Sugino; Akihiro Tsukahara; Hiroko Nakazawa; Naomune Yamamoto; Shigeki Arawaka
Journal:  BMC Neurol       Date:  2018-11-12       Impact factor: 2.474

3.  Blood-transfusion-related posterior reversible encephalopathy syndrome - A description of a new case and review of the literature.

Authors:  Mukesh Dube; Rashi Rathore
Journal:  Brain Circ       Date:  2020-12-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.